Sarepta Launches Study for Non-Ambulant ELEVIDYS Amid Persistent FDA and Operational Headwinds

What happened

Sarepta announced that screening and enrollment have begun for Cohort 8 of the ENDEAVOR study to evaluate an enhanced immunosuppression regimen with ELEVIDYS for non-ambulant Duchenne muscular dystrophy patients. This move follows the FDA's imposition of a boxed warning and restriction of ELEVIDYS to ambulatory patients only in November 2025, with non-ambulant shipments suspended since mid-2025. The cohort aims to assess prophylactic sirolimus to mitigate safety risks, potentially supporting future label expansion. However, this is an early-stage clinical effort that does not signal imminent regulatory change or resumption of non-ambulant sales, as filings indicate ongoing uncertainty over FDA actions. The initiative reflects Sarepta's long-term strategy but fails to address the near-term operational bottlenecks and regulatory overhangs dominating the investment case.

Implication

The study offers a potential pathway to broaden ELEVIDYS into the non-ambulant population, which could enhance long-term revenue if successful. However, any label expansion is years away and contingent on positive data, with no immediate impact on sales or regulatory status. Investors must prioritize monitoring Q1'26 results for evidence of ELEVIDYS catch-up infusions and improved operational KPIs, as highlighted in the DeepValue report. The initiative does not mitigate the pressing risks of further FDA restrictions on ELEVIDYS or accelerated-approval withdrawal for PMO drugs after the ESSENCE trial miss. Consequently, the WAIT rating remains appropriate, emphasizing patience until tangible progress on execution and regulatory clarity emerges.

Thesis delta

The initiation of Cohort 8 does not alter the core investment thesis, which hinges on resolving near-term FDA scrutiny and operational inefficiencies. It underscores Sarepta's commitment to label expansion but reinforces that the stock's fate depends on observable improvements in Q1'26 ELEVIDYS performance and avoidance of adverse regulatory actions. Investors should maintain a cautious stance, as this news provides no relief from the immediate risks documented in filings.